Navigation Links
Amicus Therapeutics Announces Third Quarter 2008 Financial Results
Date:11/3/2008

us' press releases are available at http://www.amicustherapeutics.com

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease.

Forward-Looking Statements

This Press release contains and the accompanying conference call will contain "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should" and "could," and similar expressions or words identify forward-looking statements. Examples of such statements include: (i) statements regarding the goals, progress and expected timing of clinical studies, including the progress, timing and design of Phase 3 clinical development for Amigal, the progress and timing of the availability of data from the Phase 2 extension study of Amigal, the progress and timing of Phase 2 clinical trials for Plicera for the treatment of Gaucher disease, the timing of the release of data from the Phase 2 clinical trials for Plicera, the initiation of Phase 2 clinical development of AT2220 for the treatment of Pompe disease, and the possibility and timin
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
2. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
3. Amicus Therapeutics Opens Research Facility in San Diego
4. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
5. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
6. Amicus Therapeutics Announces First Quarter 2008 Financial Results
7. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA ... disease. One of these latent viruses is the Epstein ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... by the theory, a study found that RA patients ... (1). , What is Microcompetition? , Dr. Hanan ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... of high throughput research solutions, today announced that ... companies, has received delivery of Freeslate’s CM ... form screening. , Lupin, headquartered in Mumbai, ... quality, affordable generic and branded formulations and Active ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, ... Foundation, the only national nonprofit organization solely dedicated to ... quality of life for those affected worldwide, will host ... Warrington Country Club in Warrington, Pa. , Each ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider ... major scientific, regulatory, business, and media events in ... , today announced its former associate Virginia Cox , ... office. Virginia Cox re-joins ... Commissioner for the Office of External Affairs at the U.S. ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2
... the journal Science today* by Microsoft Research ecologist ... University and universities in Madrid, Spain, highlight how ... to better predict environmental change. The research suggests ... which is urgently needed and now within reach, ...
... MEETING, Pa., June 12 Genaera,Corporation (Nasdaq: GENR ) ... Genaera, is scheduled to present at the BIO,Business Forum. The ... take place at the San Diego Convention Center in San,Diego ... Room 4., Armstrong will also join a panel of ...
... Ltd. (Nasdaq: XTLB ; TASE: XTL) today announced ... Extraordinary General,Meeting (collectively, the "Meetings") scheduled for July 17, ... the close of business on,June 12, 2008 are entitled ... All,shareholders are cordially invited to attend the Meetings in ...
Cached Biology Technology:Microsoft scientist highlights urgent need for new computer models to address climate change 2Microsoft scientist highlights urgent need for new computer models to address climate change 3Genaera Corporation to Present at BIO Business Forum 2Genaera Corporation to Present at BIO Business Forum 3Notification of Record Date for the Annual General Meeting and Extraordinary General Meeting 2
(Date:4/15/2014)... who study the deadliest infectious diseases recognized the contributions ... at the University of Texas Medical Branch, with a ... on Filoviruses. The filoviruses include Ebola and Marburg viruses ... people infected. The current outbreak of Ebola virus raging ... so far. , "This award represents the culmination ...
(Date:4/15/2014)... American Association of Anatomists (AAA) is honored to announce ... presented during the Closing Awards Ceremony being held at ... at 7:30 p.m. during AAA,s 2014 Annual Meeting at ... winners are: , Henry Gray/Elsevier Distinguished Educator ... of Medicine at Mount Sinai, Past-President of the American ...
(Date:4/15/2014)... cause temperatures in the Congo Basin to increase ... caused by greenhouse gases by half, according to ... Leuven, Belgium. , Explosive population growth and inefficient ... rainforests in Central Africa. A team of researchers ... practices will affect longer-term temperatures in the region. ...
Breaking Biology News(10 mins):International research group recognizes UTMB experts 2International research group recognizes UTMB experts 3American Association of Anatomists 2014 award winners 2Study: Deforestation could intensify climate change in Congo Basin by half 2
... , June 9 ADF Solutions, Inc., the leading ... to announce that it has been granted a patent by the ... data. The patent has critical applications for forensic triage, cyber-security, cyber-intelligence, ... , , ...
... undergoing assisted reproductive technology (ART) treatment should be informed ... the use of ART, the annual conference of the ... Dr. Graldine Viot, a clinical geneticist at the ... she believed that most doctors working in ART clinics ...
... A team led by researchers from the Center ... has developed a technique that someday may allow growth ... will be published in Nature Medicine and ... the structural tissue of rat livers as scaffolding for ...
Cached Biology News:USPTO Awards Key Patent to ADF Solutions for Digital Forensics 2USPTO Awards Key Patent to ADF Solutions for Digital Forensics 3Children born after assisted reproduction at greater risk of congenital malformations 2Children born after assisted reproduction at greater risk of congenital malformations 3Mass. General researchers develop functional, transplantable rat liver grafts 2Mass. General researchers develop functional, transplantable rat liver grafts 3
Agarose Gel Loading Dye Mixture 6X...
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
...
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
Biology Products: